Home>News>Events>Molnupiravir arrives in the Philippines, the first in Southeast Asia, through MedEthix, JackPharma

Molnupiravir arrives in the Philippines, the first in Southeast Asia, through MedEthix, JackPharma

In Photo (L-R): Meny Hernandez, JackPharma Inc. President; Monaliza B. Salian, MedEthix Incorporated President and CEO; Norsalem Raymond M. Mama-o, OIC PAIR CARGO Assessment Composite Division; Paolo F. Borromeo, AC Health President and CEO; Michael P. Narvaez, People’s Air Cargo & Warehousing Co. Inc. Chief Operating Officer; Ma. Victoria P. Sugapong, MedEthix Chief Operating Officer; Ruby Chiong AC Health Chief Finance Officer; Corazon Kalinga, Quickflo Forwarders Inc. President and CEO.

Manila – On November 17, 2021, the first shipment of Molnupiravir, an oral anti-viral treatment for mild COVID-19, arrived in the country through a partnership between MedEthix, one of the country’s major pharmaceutical importers and distributors, and JackPharma, a pharmaceutical distribution company. MedEthix is a member of the Ayala Healthcare Holdings, Inc. (AC Health), the healthcare arm of the Ayala Group.

Present to receive the first shipment of Molnupiravir at the PAIR Cargo Terminal, Pasay City were Monaliza B. Salian, MedEthix Co-founder, President, and Chief Executive Officer; Meny Hernandez, JackPharma Inc. President; Ma. Victoria P. Sugapong, MedEthix Chief Operating Officer; Paolo F. Borromeo, AC Health President and CEO; Ruby P. Chiong AC Health Chief Finance Officer; Dr. Rizzy A. Alejandro, AC Health Chief Public Health Officer; Michael P. Narvaez, People’s Air Cargo & Warehousing Co. Inc. Chief Operating Officer and Norsalem Raymond M. Mama-o, OIC of PAIR CARGO Assessment Composite Division. The event was facilitated by QuickFlo Forwarders, Inc., the customs brokerage partner of MedEthix and JackPharma.

Molnupiravir, brand name Molnaflu, is being imported into the country via Compassionate Special Permits (CSPs) issued by the Philippine FDA to several hospitals in the country, including AC Health’s QualiMed hospitals, as well as 30 other hospitals all over the country. The newly-arrived Molnupiravir treatment courses are supplied by Aurobindo Pharma, an Indian pharma manufacturer licensed by Merck to supply this drug to low and middle-income countries. The Philippines is the first country in Southeast Asia to receive their supply of Molnupiravir and will be available to the public as of today.

“We are delighted to announce that MedEthix has leveraged its core strength of forging alliances, with the likes of JackPharma who is its appointed national distributor of Molnupiravir, and of QuickFlo Forwarders, which has represented MedEthix before the Bureau of Customs, that, in turn, enabled MedEthix to be recognized as a Super Green Lane holder” shared Monaliza B. Salian, President and CEO of MedEthix.

“Indeed, today is a celebration also of AC Health’s lead role in the entire Ayala Corporation’s group of companies, to put its share towards contributing to national recovery. #AyalaForPH and AC Health will pledge to ensure the continued availability of Molnupiravir (Molnaflu) treatment courses in all its CSP grantees-hospitals, to our underprivileged countrymen, via all AC Health patient touch points” shared Ma. Victoria P. Sugapong, Chief Operating Officer of MedEthix.

The drug, developed by Emory University and Merck, was shown in clinical trials to reduce the risk of hospitalization and death by 50% for patients with mild COVID-19. Molnupiravir could potentially help reduce the burden of COVID-19 to the healthcare system by providing a much-needed option for outpatient treatment to prevent progression to severe disease and death.

Under a CSP, patients diagnosed with mild COVID-19 can be prescribed Molnupiravir, and can avail of the drug from a hospital granted a CSP. Molnupiravir comes in a 200mg capsule with a recommended regimen of 800mg (4 capsules) to be taken twice a day for 5 days or as prescribed by a physician. It will be available in a bottle of 40 capsules to cover the entire treatment regimen.

“We are delighted that MedEthix and JackPharma have made it possible to bring Molnupiravir into the country. This drug is a game-changer, and we look forward to offering this life-saving medicine to our patients at QualiMed. Moreover, we are extremely proud that, through the efforts of MedEthix and JackPharma, Molnupiravir will be available nationwide for our countrymen at an affordable price. This is very much in line with the commitment of AC Health and the Ayala Group to support the country’s COVID-19 response efforts,” said Paolo Borromeo, AC Health President & CEO.

Earlier in the pandemic, AC Health, with the help of its partners, built and capacitated 8 RT-PCR labs for COVID-19 testing, and converted its 4 QualiMed hospitals in Sta Rosa, Laguna; San Jose Del Monte, Bulacan; Tanauan, Batangas, and Iloilo City into COVID-19 referral hospitals. More recently, AC Health has become one of the largest Healthcare Service Providers of COVID-19 vaccines, and has administered close to 600,000 doses in over 25 vaccination sites across the country.

AC Health

Ayala Healthcare Holdings, Inc. (AC Health) is a wholly-owned subsidiary of the Ayala Corporation, and serves as the portfolio company for healthcare businesses. Its vision is to build an ecosystem that links every patient to a seamless healthcare experience. Its portfolio includes Generika Drugstore, the pioneer in generic retail pharmacies, IE Medica and MedEthix, major pharmaceutical importer and distributor, Healthway, a network of primary care, multi-specialty, and corporate clinics, and QualiMed, a comprehensive network of full-service hospitals, multi-specialty clinics, and a stand-alone day surgery center. AC Health has also invested in health technology solutions, most recently, HealthNow, a healthcare aggregator app that offers online consultations, medicine delivery, and clinic and diagnostic booking.

Journal Online
A collection of noteworthy information on various topics from the Philippines and the rest of the world.